Ironwood Pharmaceuticals (IRWD) director Denner received 67,546 shares
Insider transactions reported
Alexander J Denner (director at Ironwood Pharmaceuticals Inc., IRWD) reported that they received 67,546 shares between Jun 15, 2026 and Jun 16, 2026. After these transactions the filing shows 323,855 shares held directly.
- Reporting person
- Denner Alexander J
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jun 15, 2026 | Grant or award (A) | Class A Common Stock1 | +4,065 | - | - | 260,374 direct |
| Jun 16, 2026 | Grant or award (A) | Class A Common Stock2 | +63,481 | - | - | 323,855 direct |
Holdings before and after
- Class A Common Stock: 256,309 to 323,855 direct
Footnotes from the filing
- 1. Issued pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024.
- 2. The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Denner report in this IRWD Form 4?
Alexander J Denner (director at Ironwood Pharmaceuticals Inc., IRWD) reported that they received 67,546 shares between Jun 15, 2026 and Jun 16, 2026. After these transactions the filing shows 323,855 shares held directly.
How many IRWD shares does Denner hold after this filing?
The filing shows 323,855 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for IRWD
Across the 12 sessions after earlier IRWD headlines, the stock closed higher 5 times and lower 7 times, with a median move of 7.6% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
Earlier insider filings at IRWD
- Jun 17, 2026Director Mchugh Julie sold $80,460 worth of shares (21,571 units at $3.73) as part of a pre-agreed trading plan and was granted 63,481 shares, increasing direct ownership by 20% to 250,749 units (SEC Form 4)
- Jun 17, 2026Director Moukheibir Catherine was granted 63,481 shares, increasing direct ownership by 54% to 181,425 units (SEC Form 4)
- May 21, 2026PFO & PAO Silver Ronald was granted 25,000 shares, increasing direct ownership by 6% to 441,570 units (SEC Form 4)
- Mar 18, 2026Director Denner Alexander J was granted 4,451 shares and sold $20,530,448 worth of shares (6,730,800 units at $3.05), increasing direct ownership by 2% to 256,309 units (SEC Form 4)
- Mar 12, 2026Chief Legal Officer John Minardo was granted 136,612 shares, increasing direct ownership by 38% to 500,498 units (SEC Form 4)
Keep researching IRWD
- IRWD insider tradesEvery buy and sale reported by Ironwood Pharmaceuticals Inc. officers, directors and large holders.
- What is Form 4?The SEC filing that reports a change in an insider's holdings, such as a purchase, sale, option exercise or grant, generally within two business days.
- Form 4 explainedForm 4 is the SEC filing that discloses when officers, directors and 10% owners buy or sell company stock, due within 2 business days. Learn every key field and code.
- Insider trading trackerThe latest insider buys and sales across every stock.
- IRWD earnings historyPast Ironwood Pharmaceuticals Inc. earnings releases, newest first.
- IRWD financial statementsRevenue, profit, cash flow and balance sheet from Ironwood Pharmaceuticals Inc.'s SEC filings.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2010
Follow IRWD and get a push notification the moment its next story breaks.